Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03104738
Other study ID # 2013H0232
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 20, 2013
Est. completion date August 18, 2016

Study information

Verified date September 2019
Source Ohio State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Many patients with Type 2 Diabetes Mellitus (T2DM) are currently being managed with Basal Insulin (BI). However, there is little evidence to support guidelines on dosing adjustments in the preoperative period. The Society for Ambulatory Anesthesia does not advise a reduction in the dose of BI preoperatively, unless there is a specific history of hypoglycemia. The Endocrine Society suggests a 50% reduction in BI dose the evening before surgery. The authors hypothesized that a 25% reduction in BI dose the evening before surgery will result in better perioperative blood glucose control compared with our institutional 50% decrease.


Description:

A total of 40 subjects diagnosed with T2DM taking once-daily evening BI, scheduled to undergo elective surgery under general anesthesia will be consented and randomized in a 1:1 ratio to received either 50% or 25% reduction of their regular evening BI dose on the evening before surgery. Blood glucose levels (BGL) will be recorded perioperatively according to institutional guidelines.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date August 18, 2016
Est. primary completion date August 18, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects who have volunteered and consented to participation in the study during their outpatient preoperative anesthesia appointment.

- Type II Diabetics taking once-daily evening basal insulin (glargine or detemir)

- Patients that will undergo general anesthesia

- Patients who have been on basal insulin for = 3months

Exclusion Criteria:

- Inability to read, comprehend, and sign informed consent

- Patients with Type I Diabetes

- Patients who take short-acting insulin boluses which make up greater than 20% of their total daily insulin dose

- Patients who have been on chronic steroids = 5 mg/dl prednisone daily or equivalent for = 1 month within the past 12 months

- Pregnant patients

- Patients on twice-daily dosing of basal insulin

- Patient who take basal insulin in the morning

- Patients with a history of severe hypoglycemia, defined as any event in the previous year requiring assistance of another person to actively administer carbohydrate, glucagons, or other resuscitative actions

- Patients that will undergo cardiac, transplant, or brain surgeries

- Prisoners

Study Design


Related Conditions & MeSH terms


Intervention

Other:
25% reduction of basal insulin dose
Subjects will be instructed to reduce their basal insulin dose to 75% instead of our institutional 50%. Subject must check their own blood sugar before reporting to the hospital for their surgery. If the value is less than 70 or subjects are having symptoms of hypoglycemia, subjects will be instructed to immediately ingest 4-8 oz of fruit juice (without pulp) and call their doctor or the hospital.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ohio State University

Outcome

Type Measure Description Time frame Safety issue
Primary Pre-operative Fasting Blood Glucose, as Measured by Standardized Point of Care Capillary Blood Glucose (CBG) Device in the Pre-op Holding Area. Capillary blood glucose before surgery, considering a fasting period up to 8 hours prior fasting blood glucose Hospital arrival - Anesthesia start time. The time period did not exceed 4 hours, considering that surgeries were scheduled to be morning cases.
Secondary Incidence of Preoperative Hypoglycemia Capillary blood glucose level <80 mg/dl Hospital arrival - Anesthesia start time. The time period did not exceed 4 hours, considering that surgeries were scheduled to be morning cases.
Secondary Incidence of Preoperative Hypoglycemia Requiring Ingestion of Juice Prior to Arrival to the Hospital Capillary blood glucose level <70 mg/dl Basal insulin dose administration the evening before surgery - Hospital arrival the morning of the surgery. The time period did not exceed 12 hours, considering a fasting period up to 8 hours and a preoperative period up to 4 hours.
Secondary Incidence of Preoperative Hyperglycemia Capillary blood glucose level >179 mg/dl Hospital arrival - Anesthesia start time. The time period did not exceed 4 hours, considering that surgeries were scheduled to be morning cases
Secondary Incidence of Intraoperative Hyperglycemia Capillary or arterial/venous blood glucose level >179 mg/dl Anesthesia start time - Anesthesia stop time. The time period did not exceed 10 hours, considering type of surgeries or procedures.
Secondary Incidence of Patients Requiring Initiation of Perioperative IV Insulin Drip Hospital arrival - 24 hours postoperatively.
Secondary Incidence of Hyperglycemia in the Post-anesthesia Care Unit (PACU) to 24 Hours Post-operatively Capillary or arterial/venous blood glucose level >179 mg/dl Anesthesia stop time - 24 hours postoperatively.
Secondary Incidence of Symptomatic Hypoglycemia Requiring Treatment in the PACU to 24 Hours Post-operatively Capillary or arterial/venous blood glucose level <70 mg/dl Anesthesia stop time - 24 hours postoperatively.
Secondary Incidence of Hypoglycemia in the PACU to 24 Hours Post-operatively Capillary or arterial/venous blood glucose level <80 mg/dl Anesthesia stop time - 24 hours postoperatively.
Secondary Incidence of Surgical Delay or Cancellation Due to Hyperglycemia Hospital arrival - Surgery start date/time. The time period did not exceed 4 hours, considering that surgeries were scheduled to be morning cases
Secondary Mean 24-hour Glucose Postoperatively Anesthesia stop time - 24 hours postoperatively
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Active, not recruiting NCT02248311 - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population N/A
Completed NCT02653300 - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) Phase 2
Completed NCT03655535 - Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes Phase 2
Completed NCT03256747 - Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes N/A
Completed NCT05343767 - Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus N/A
Withdrawn NCT03675074 - Neujia Anastomosis for Treatment of Obesity and Type II Diabetes N/A
Withdrawn NCT03190798 - Effects of Canagliflozin on Intravascular Volume and Hemodynamics Phase 4
Active, not recruiting NCT03437330 - Empagliflozin Effect on Glucose Toxicity Phase 4
Withdrawn NCT03008395 - Empowerment, Motivation and Medical Adherence (EMMA). N/A
Not yet recruiting NCT05539066 - AI Health Assistant and Type 2 Diabetes N/A
Completed NCT03682445 - Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus N/A
Not yet recruiting NCT03239119 - The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus Phase 3
Completed NCT03259789 - Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Phase 3
Recruiting NCT03506230 - Financial Incentives for Low Socioeconomic Diabetic Patients N/A
Completed NCT03072407 - MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM Phase 1
Completed NCT05668442 - Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
Completed NCT02956044 - Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Phase 1
Completed NCT02964572 - Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes N/A
Completed NCT02628392 - A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) N/A